A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy

Duan, Yajun; Zheng, Jian; Han, Sufang; Wu, Yi Hui; Wang, Yanming; Li, Deguan; Kong, Deling; Yu, Yaoting

doi:10.1016/j.jconrel.2008.01.016

Cited by 33 publications

(34 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Magnetic nanoparticles coated with polyethene glycol which avoid the identification or capture by reticuloendothelial system, due to opsonin absorbance onto magnetic nanoparticles and phagocytosis carried out by macrophagic cells [21][22]. Antibody targeting of tumour-associated antigens or cell surface protein like tumor necrosis factor receptor enhances the selectivity or targeting effect in cancer tissues like renal cell carcinoma [23].…”

Section:  Antibody Conjugated Magnetic Nanoparticles Induced Hyperthmentioning

confidence: 99%

Development Status in the Meadow of Nanostructure Magnetic Drug Delivery System and Its Promising Applications

Powar

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

This article discusses about magnetic nanoparticles, their physicochemical properties various applications in medicinal sectors and technology advancements. Superparamagnetic, high magnetic susceptibility, non-toxicity, and biocompatibility and less Curie temperature are critical characteristics of magnetic nanoparticles which make them suitable for assorted medical applications. Now a day's magnetic particles play a significant role in diverse technological areas with potential applications in fields such as electronics, energy biomedicine and diagnosis. Magnetic nanoparticles have been a vivacious topic of extreme research for the last fifty years due to its top-down approaches. The perspective of magnetic nanoparticles stems from the fundamental characteristics of their magnetic cores collective with their drug loading capability, biochemical properties. This article review the modern advancement of magnetic nanoparticles for drug delivery, focusing chiefly on the impending applications like targeted drug delivery, bioseparation, magnetic resonance and cancer diagnosis, induction of hyperthermia, induction of hyperthermia, nanorobotic agents, tissue engineering, artificial muscle, magnetically activated polymers, controlled tissue assembly, control cell function, bone regeneration scaffold, destruction of blood clots, labeling stem cells with magnetic nanoparticles, implant-assisted intrathecal magnetic drug targeting, biodegradable magnetic nano-composite stent, local drug delivery etc.

show abstract

Section:  Antibody Conjugated Magnetic Nanoparticles Induced Hyperthmentioning

confidence: 99%

Development Status in the Meadow of Nanostructure Magnetic Drug Delivery System and Its Promising Applications

Powar

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

show abstract

“…The targeted delivery of the lipoplexes may be achieved through the addition of targeting moieties (e.g., ligands) into liposomes by direct formulation, with no covalent bond to any lipid (Seol et al, 2000); conjugated to helper lipid (Dauty et al, 2002), or connected directly to the cationic lipids (Kawakami et al, 2000a;Gaucheron et al, 2001c). For targeted lipoplexes, modified with a targeting moiety such as folate (Dauty et al, 2002), galactose (Kawakami et al, 2000a;Gaucheron et al, 2001c), mannose (Kawakami et al, 2000b), antibodies (Duan et al, 2008) and transferrin (Seol et al, 2000;Sakaguchi et al, 2008), the uptake can be receptor mediated and enhanced . Targeting of the folate receptor (FR) had received much attention in recent years, since the folate receptor is a tumor marker over expressed in large numbers of cancer cells, including cancers of the ovary, kidney, uterus, testis, brain, colon, and in addition, folic acid is a relatively small molecule (MW 441 Da), therefore, it has the advantages of being stable and nonimmunogenic compared to monoclonal antibodies (Kane et al, 1986), and still having a relatively high receptor affinity.…”

Section: Conjugates Of Targeting Moieties and Lipidsmentioning

confidence: 99%

Cationic Liposomes in Different Structural Levels for Gene Delivery

Zhao¹,

Zhi²,

Zhang³

2011

Non-Viral Gene Therapy

View full text Add to dashboard Cite

“…In apoptotic cells, Hoechst 33258 assay revealed the appearance of a collection of multiple chromatin and fragmented apoptotic nuclei. G250-PEI-(PEG550) 10 cyto-compatibility is improved compared to PEI [5,6] , so there is minimal of apoptotic cells when transfected with plasmid pEGFP. Since NIH3T3 cells do not express NS gene in a high level, pEGFP6-1-NS-Silencer plasmid will not inhibit cell proliferation, and will not cause subsequent apoptosis either.…”

Section: Hoechst 33258 Stainingmentioning

confidence: 99%

“…Promoted anti-tumor effect was reported via the EGFR, VEGFR on the cell surface in tumor targeted gene therapy [3] . Previously, HeLa cells were observed to express G250 antigen on the surface of the cell membrane [4] with the tumor targeted vector, the G250 mAb modified PEI [5] . Polyethylene glycol (PEG), with the high solubility in water, can reduce immunogenicity and improve biocompatibility, and has been coupled to PEI to improve the solubility of complexes and transfection efficiency in drug delivery systems [6] .…”

mentioning

confidence: 99%

Non-viral gene carrier mediated short hairpin RNA interference for inhibition of tumor cells growth

et al. 2009

Self Cite

View full text Add to dashboard Cite

A tumor-targeting gene vector G250mAb-PEI-PEG has been prepared by modification of polyethylenimine (PEI) with polyethyleneglycol (PEG) and G250, a monoclonal antibody against the G250 antigen on tumor cell surface. The transfection efficiency was as high as 70% in G250 positive HeLa cells, whereas the transfection efficiency was relatively low (30%) in normal NIH3T3 cells. A plasmid encoding the short hairpin RNA (shRNA) specific for nucleostemin gene (NS) was efficiently transfected into the HeLa cells with this nonviral gene vector. RNA interference down-regulated the expression of NS gene in HeLa cells, inhibited cells proliferation and induced apoptosis. However, the growth and activity of the NIH3T3 cells were not affected under the same treatment.These results indicate that the reported nonviral gene vector, G250mAb-PEI-PEG, can target and efficiently deliver genes into HeLa cells, and has the potential for the cervical cancer treatment.

show abstract

A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy

Cited by 33 publications

References 30 publications

Development Status in the Meadow of Nanostructure Magnetic Drug Delivery System and Its Promising Applications

Development Status in the Meadow of Nanostructure Magnetic Drug Delivery System and Its Promising Applications

Cationic Liposomes in Different Structural Levels for Gene Delivery

Non-viral gene carrier mediated short hairpin RNA interference for inhibition of tumor cells growth

Contact Info

Product

Resources

About